Mean improvement in disability · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
Improvement in 10‐metre walk time at 8 to 12 months1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
Participant subjective impression of change stable or improved at 8 to 12 months · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
Rituximab may leads to higher participant subjective impression of change stable or improved at 8… compared with placebo (low certainty).
1 finding from 1 review
Change in serum IgM paraprotein concentration 8 months after treatment1 · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1 finding from 1 review
Any adverse event · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
It is very uncertain whether rituximab changes any adverse event compared with placebo (very low certainty).
1 finding from 1 review
QoL · people with active UC
1 finding from 1 review
Comparison intervention · relapsing multiple sclerosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Disability worsening · relapsing multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · relapsing multiple sclerosis
Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · relapsing multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Cancer · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
— · relapsing multiple sclerosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Interferons or glatiramer acetate · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes interferons or glatiramer acetate compared with other disease‐modifying treatments (very low certainty).
1 finding from 1 review
HR 0.86 [0.52, 1.42]
853 participants
Very low
Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · relapsing multiple sclerosis
Rituximab as 'switching' probably leads to lower fingolimod compared with other disease‐modifying treatments (moderate certainty).
2 findings from 1 review
HR 0.08 [0.02, 0.32]
256 participants
Moderate
HR 0.26 [0.04, 1.69]
137 participants
Very low
Natalizumab · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes natalizumab compared with other disease‐modifying treatments (very low certainty).
2 findings from 1 review
HR 1 [0.2, 5]
153 participants
Very low
HR 0.24 [0.06, 1]
170 participants
Low
Interferon beta or glatiramer acetate · relapsing multiple sclerosis
Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).
2 findings from 1 review
OR 1.71 [1.11, 2.62]
5477 participants
Moderate
HR 0.14 [0.05, 0.39]
335 participants
Moderate
Ocrelizumab · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes ocrelizumab compared with other disease‐modifying treatments (very low certainty).
1 finding from 1 review
OR 0.02 [0, 0.4]
472 participants
Very low